The standard regimen of omalizumab is often modified in patients with chronic spontaneous urticaria, with several factors predicting dose adjustments.

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

As seasons change, temperatures rise and flowers begin to bloom, many find themselves battling more than just spring fever, ...

The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib ...

Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab ...

U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a 45mg/0.5mL solution in a single-dose vial for ...

Anaphylaxis is treated as indicated. For chronic cases, several sources suggest considering the use of omalizumab (Xolair), the case authors wrote, adding that some chronic cases resolve ...

Xolair (omalizumab) has been around since the early 2000s as a treatment for severe allergic asthma, but found a new lease of life in 2014 when it was approved for CSU, with sales reaching $1.4 ...

Novartis’ anti-IgE antibody Xolair (omalizumab) has been a mainstay of treatment for refractory CSU for many years. However, the drug is heading for patent expiry in Europe this year and in the ...

A recent study suggests that an asthma drug, omalizumab, could potentially prevent allergic reactions to food, including peanuts. unbranded - Newsworthy unbranded - Newsworthy Watch Next ...